
Immersion remains a value play, trading ~26.4% below its estimated $9/share underlying value. IMMR's upside is now more tied to BNED's turnaround and ongoing equity investments, as patent monetization catalysts have weakened and patent portfolio value is uncertain. The company maintains strong liquidity, no debt, and a forward dividend yield near 4.5%, providing a moderate baseline return for patient investors.


